Hinge Health (NYSE:HNGE) Shares Gap Up – Still a Buy?

Hinge Health Inc. (NYSE:HNGE)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $33.05, but opened at $38.50. Hinge Health shares last traded at $35.3690, with a volume of 1,816,589 shares traded.

Key Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q4 beat — Hinge reported $0.31 EPS vs. consensus $0.04 and revenue of $170.7M versus $157.3M expected; revenue grew ~45.5% year-over-year, which directly explains the rally. Read More.
• Positive Sentiment: Upside guidance — Hinge raised FY2026 revenue guidance to $732M–$742M (above the $701.6M consensus) and guided Q1 revenue to $171M–$173M (above the $159.9M consensus), signaling stronger forward growth and supporting the stock move. Read More.
• Positive Sentiment: Growth strategy & AI investment — Management outlined a ~25% 2026 revenue growth target and highlighted investments in AI-driven care that could expand margins and product differentiation over time. Read More. Read More.
• Positive Sentiment: Analyst bullishness — Several firms reaffirmed positive ratings and high targets (Needham buy with $59 PT; Citizens Jmp market outperform with $65 PT), reinforcing investor confidence and providing additional upside narratives. Read More. Read More.
• Neutral Sentiment: Market commentary & recaps — Multiple outlets published explainers and the full Q4 earnings call transcript (useful for detail but largely descriptive of the moves above). Read More. Read More.
• Negative Sentiment: Analyst trim — Barclays cut its price target from $60 to $52 (still “overweight”), showing some analyst-level caution about valuation despite the beat; divergent PTs create mixed views on how much upside is realistic. Read More.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HNGE. Canaccord Genuity Group set a $53.00 price objective on Hinge Health in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and set a $59.00 target price on shares of Hinge Health in a report on Wednesday. Citizens Jmp restated a “market outperform” rating and set a $65.00 price target on shares of Hinge Health in a research report on Wednesday. Wells Fargo & Company started coverage on Hinge Health in a research report on Thursday, January 8th. They issued an “overweight” rating and a $68.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Hinge Health in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Hinge Health has a consensus rating of “Moderate Buy” and an average target price of $58.59.

Hinge Health Trading Up 10.4%

The business has a fifty day moving average of $44.11 and a 200-day moving average of $48.93. The company has a market cap of $2.87 billion and a PE ratio of -2.77.

Hinge Health declared that its board has initiated a stock buyback plan on Wednesday, November 12th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 7.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other news, President James Pursley sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $48.40, for a total value of $726,000.00. Following the completion of the sale, the president directly owned 769,778 shares of the company’s stock, valued at approximately $37,257,255.20. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kristina M. Leslie sold 1,250 shares of Hinge Health stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $45.68, for a total transaction of $57,100.00. Following the sale, the director directly owned 27,750 shares in the company, valued at $1,267,620. The trade was a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,805,105 shares of company stock valued at $128,216,614 over the last three months.

Institutional Trading of Hinge Health

Several large investors have recently bought and sold shares of HNGE. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Hinge Health in the 3rd quarter worth approximately $37,000. Montag A & Associates Inc. bought a new stake in shares of Hinge Health during the second quarter valued at approximately $41,000. First Horizon Corp grew its stake in Hinge Health by 163.9% in the fourth quarter. First Horizon Corp now owns 855 shares of the company’s stock worth $40,000 after purchasing an additional 531 shares during the period. SBI Securities Co. Ltd. bought a new position in Hinge Health in the second quarter worth $48,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in Hinge Health during the third quarter valued at $49,000.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.